Multiple Sclerosis and Related Disorders

Papers
(The TQCC of Multiple Sclerosis and Related Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The COVID-19 pandemic and the use of MS disease-modifying therapies133
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?127
Multiple sclerosis following SARS-CoV-2 infection119
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran117
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain109
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients106
Effects of MS disease-modifying therapies on responses to vaccinations: A review.103
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms98
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment84
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States78
A case of possible atypical demyelinating event of the central nervous system following COVID-1975
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.70
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis68
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report68
Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment64
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod63
Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life61
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic60
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review57
Infections in patients diagnosed with multiple sclerosis: A multi-database study57
Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak56
Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study55
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab53
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study50
COVID-19 in ocrelizumab-treated people with multiple sclerosis50
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies49
Genetic Acute Necrotizing Encephalopathy Associated with RANBP2: Clinical and Therapeutic Implications in Pediatrics46
Long COVID or post COVID-19 syndrome46
COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series46
MOG-associated encephalitis following SARS-COV-2 infection45
A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.44
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review43
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 202142
Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice42
Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial41
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?40
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis39
Prodromal headache in MOG-antibody positive optic neuritis39
Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients38
The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance38
Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature38
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-1937
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases36
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis36
Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients36
A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis36
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?35
The effect of aquatic physical therapy on patients with multiple sclerosis: A systematic review and meta-analysis35
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England35
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach35
Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review35
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice35
Rethinking high-risk groups in COVID-1934
Comparison of the effects of two different exergaming systems on balance, functionality, fatigue, and quality of life in people with multiple sclerosis: A randomized controlled trial34
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis34
Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis34
Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children34
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-1934
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies33
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America33
Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)33
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis33
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis32
Effectiveness of Virtual Reality Rehabilitation in Persons with Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials32
Patients' perspective and usability of innovation technology in a new rehabilitation pathway: An exploratory study in patients with multiple sclerosis32
Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica32
Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis32
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders32
Adherence and drop-out in randomized controlled trials of exercise interventions in people with multiple sclerosis: A systematic review and meta-analyses31
Feasibility and treatment effect of cognitive behavioral therapy for insomnia in individuals with multiple sclerosis: A pilot randomized controlled trial31
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis31
Infections in patients with multiple sclerosis: A national cohort study in Sweden31
Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes30
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report30
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects30
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab30
COVID-19 vaccine associated demyelination & its association with MOG antibody30
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia30
The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity29
Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy29
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab29
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical – Paraclinical follow up study of a case29
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis29
T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers29
Efficacy of robot-assisted gait training in multiple sclerosis: A systematic review and meta-analysis28
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis28
Autoimmune encephalitis associated with COVID-19: A systematic review28
Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways28
COVID-19 and emerging spinal cord complications: A systematic review27
Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series27
Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial27
Anti-MOG associated disorder–Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD–A single-center experience27
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?27
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic27
Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review26
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1926
Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use26
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis26
Objective sensor-based gait measures reflect motor impairment in multiple sclerosis patients: Reliability and clinical validation of a wearable sensor device26
Fear of falling and falls in people with multiple sclerosis: A literature review26
Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey25
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies25
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy25
Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis25
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab25
Multiple sclerosis and aging: comorbidity and treatment challenges25
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration25
Social cognition in multiple sclerosis and its subtypes: A meta-analysis25
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial25
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab25
Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population24
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients24
Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials24
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis24
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab24
Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic24
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness24
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients24
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience24
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab24
Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.23
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience23
Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases23
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia23
Characteristics of COVID-19 disease in multiple sclerosis patients23
Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial23
A new look at an old test: Normative data of the symbol digit modalities test –Oral version23
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data23
Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review23
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases22
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years22
An overview of lipidomic analysis in different human matrices of multiple sclerosis22
Long-term dynamics of multiple sclerosis iron rim lesions21
Vaccine hesitancy among people with multiple sclerosis21
How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey21
Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001–201521
Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories21
Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis21
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD21
Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis21
Normal antibody response after COVID-19 during treatment with cladribine21
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge21
Depression in multiple sclerosis: Is one approach for its management enough?20
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod20
Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran20
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis20
Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review20
African Americans experience disproportionate neurodegenerative changes in the medulla and upper cervical spinal cord in early multiple sclerosis20
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis20
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS20
Autoimmune glial fibrillary acidic protein astrocytopathy mimics infectious meningitis: Two case reports20
The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades20
The role of the clinical nurse specialist multiple sclerosis, the patients’ and families’ and carers’ perspective: An integrative review20
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters20
Longitudinally extensive transverse myelitis following acute COVID-19 infection20
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab20
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–201720
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy20
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?20
Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder20
Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic19
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program19
Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-1919
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS19
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies19
Effects on gait and balance of home-based active video game interventions in persons with multiple sclerosis: A systematic review19
Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran19
Tired of not knowing what that fatigue score means? Normative data of the Modified Fatigue Impact Scale (MFIS)19
Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review and meta-analysis19
One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients19
Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients19
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis19
Early predictors of conversion to secondary progressive multiple sclerosis19
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients19
Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil19
¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis19
Multiple sclerosis incidence: A systematic review of change over time by geographical region19
Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis19
Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients19
Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis19
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study18
Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics18
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets18
High or increasing serum NfL is predictive of impending multiple sclerosis relapses18
Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder18
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod18
Smartphone applications to assess gait and postural control in people with multiple sclerosis: A systematic review18
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study18
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?18
Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis18
The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients18
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis18
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab18
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis18
Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis18
Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood–brain barrier breakdown and peripheral plasmablasts18
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study18
Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis18
COVID-19 in MS and NMOSD: A multicentric online national survey in Chile18
Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis17
The rs4759314 SNP within Hotair lncRNA is associated with risk of multiple sclerosis17
Home-Based Exercise Training in Multiple Sclerosis: A Systematic Review with Implications for Future Research17
Status of the neuromyelitis optica spectrum disorder in Latin America17
Sex-specific differences in rim appearance of multiple sclerosis lesions on quantitative susceptibility mapping17
Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases17
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis17
Artificial intelligence in the diagnosis of multiple sclerosis: A systematic review17
“No evidence of disease activity”: Is it an aspirational therapeutic goal in multiple sclerosis?17
How personality traits affect functional outcomes in patients with multiple sclerosis: A scoping review on a poorly understood topic17
CNS demyelination during tofacitinib therapy: First report17
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID17
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection17
“FLAMES: A novel burning entity in MOG IgG associated disease”17
Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare17
Exercise improves neurotrophins in multiple sclerosis independent of disability status17
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis17
The impact of balance specific physiotherapy, intensity of therapy and disability on static and dynamic balance in people with multiple sclerosis: A multi-center prospective study17
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)17
The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis16
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies16
Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country16
Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)16
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland16
Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic review and meta-analysis16
Use of natalizumab in persons with multiple sclerosis: 2022 update16
Dual task training effects on gait and balance outcomes in multiple sclerosis: A systematic review16
Aquatic exercising may improve sexual function in females with multiple sclerosis – an exploratory study16
Idebenone does not inhibit disability progression in primary progressive MS16
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics16
Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases16
A case of GFAP-astroglial autoimmunity presenting with reversible parkinsonism16
Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate16
Effects of a 10-week multimodal dance and art intervention program leading to a public performance in persons with multiple sclerosis - A controlled pilot-trial16
Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review16
MSCOVID19: Using social media to achieve rapid dissemination of health information16
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study16
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis16
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.16
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses16
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab16
Fatigue and fluctuations in physical and psychological wellbeing in people with multiple sclerosis: A longitudinal study16
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review16
The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis15
A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT)15
The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs15
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey15
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study15
Working ability in individuals with different disease courses of multiple sclerosis: Factors beyond physical impairment15
COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis15
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder15
0.038177013397217